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Abstract
Background: Smoking rates are high in adults with anxiety disorders (ADs), yet little
is known about the safety and efficacy of smoking‐cessation pharmacotherapies in
this group.
Methods: Post hoc analyses in 712 smokers with AD (posttraumatic stress disorder
[PTSD], n = 192; generalized anxiety disorder [GAD], n = 243; panic disorder [PD],
n = 277) and in a nonpsychiatric cohort (NPC; n = 4,028). Participants were randomly
assigned to varenicline, bupropion, nicotine‐replacement therapy (NRT), or placebo
plus weekly smoking‐cessation counseling for 12 weeks, with 12 weeks follow‐up.
General linear models were used to test the effects of treatment group, cohort, and
their interaction on neuropsychiatric adverse events (NPSAEs), and continuous
abstinence weeks 9–12 (treatment) and 9–24 (follow‐up).
Results: NPSAE incidence for PTSD (6.9%), GAD (5.4%), and PD (6.2%) was higher versus
NPC (2.1%), regardless of treatment. Across all treatments, smokers with PTSD (odds ratio
[OR] = 0.58), GAD (OR=0.72), and PD (OR=0.53) had lower continuous abstinence rates
weeks 9–12 (CAR9–12) versus NPC. Varenicline demonstrated superior efficacy to
placebo in smokers with GAD and PD, respectively (OR=4.53; 95% confidence interval
[CI] = 1.20–17.10; and OR=8.49; 95% CI = 1.57–45.78); NRT was superior to placebo in
smokers with PD (OR=7.42; 95% CI =1.37–40.35). While there was no statistically
significant effect of any treatment on CAR9–12 for smokers with PTSD, varenicline
improved 7‐day point prevalence abstinence at end of treatment in this subcohort.
Conclusion: Individuals with ADs were more likely than those without psychiatric illness
to experience moderate to severe NPSAEs during smoking‐cessation attempts, regardless
of treatment. While the study was not powered to evaluate abstinence outcomes with
these subgroups of smokers with ADs, varenicline provided significant benefit for cessation
in those with GAD and PD, while NRT provided significant benefit for those with PD.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Clinical trial registration: ClinicalTrials.gov, identifier NCT01456936
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1 | INTRODUCTION
Individuals with anxiety disorders (ADs) smoke tobacco at rates 2–3
fold higher than those without mental health conditions (Cougle,
Zvolensky, Fitch, & Sachs‐Ericsson, 2010; Lasser et al., 2000; McCabe
et al., 2004). Like other smokers with mental health conditions (Evins,
Cather, & Laffer, 2015), smokers with AD typically smoke more
heavily (Kelly, Jensen, & Sofuoglu, 2015a), are more severely
nicotine‐dependent (Okoli, Otachi, Manuel, & Woods, 2018), and
experience earlier and more severe nicotine‐withdrawal symptoms
(Piper, Cook, Schlam, Jorenby, & Baker, 2011) than smokers without
mental health conditions, making quitting smoking more challenging
(Kelly et al., 2015b). Despite this high rate of co‐occurrence and
greater difficulty quitting, relatively few randomized controlled trials
(RCTs) have evaluated the safety and efficacy of the front‐line
smoking cessation pharmacotherapies in smokers with AD. More-
over, most RCTs conducted to date of smoking cessation interven-
tions for smokers with AD included no placebo control or comparison
group of smokers without mental health conditions, focused on one
AD condition at a time, and tested only one of the US Food and Drug
Administration (FDA)‐approved medications in that AD subcohort.
Thus, there are insufficient data to draw comparisons across
different diagnostic subgroups of smokers with AD, control smokers,
and smoking cessation medications.
A notable exception was the retrospective analysis of a placebo‐
controlled RCT of nicotine‐replacement therapy (NRT) and bupropion
in a subcohort of smokers who endorsed prior panic attacks (not
necessarily meeting criteria for panic disorder [PD]), social phobia, or
generalized anxiety disorder (GAD; Piper et al., 2011). Smokers with
AD in this study had lower abstinence rates than smokers without
mental health conditions and appeared to derive no added benefit
from bupropion, NRT, or their combination over placebo plus
counseling. While there was some specificity between the subtype
of ADs, the results were more similar than different. To our
knowledge, no placebo‐controlled RCTs have examined the efficacy
of varenicline in smokers with ADs, most likely reflecting a reluctance
to prescribe this effective medication to individuals with ADs because
of concerns raised about its neuropsychiatric safety (Anthenelli et al.,
2016). For example, a retrospective chart review of 78 smokers with
posttraumatic stress disorder (PTSD) found an increased number of
mental health encounters while subjects were taking varenicline
compared with a pretreatment baseline period (Campbell &
Anderson, 2010). Such findings raised concerns about the use of
varenicline in smokers with PTSD, yet without the inclusion of
placebo control, the mental health encounters cannot be attributed
to medication effects. Further, given the historical concerns about
varenicline and subsequent restrictions placed on its use by several
federal agencies (Federal Aviation Administration, 2008; US
Department of Defence, 2008), including the Department of
Veterans Affairs Health System for patients with mental health
conditions
(US Department of Veterans Affairs et al., 2008, July 2011),
examining varenicline in the largest randomized trial to date will
provide critical safety information to guide policies and practices.
Given the paucity of safety and efficacy data from methodolo-
gically rigorous, placebo‐controlled RCTs of pharmacotherapeutic
cessation aids, clinicians have had little guidance on how to advise
patients with specific AD diagnoses about which cessation treatment
might work best for them. It is also not clear whether cessation
obstacles equally cut across this heterogeneous group of mental
health conditions (i.e., PTSD, GAD, and PD with/without agorapho-
bia) that form the broader AD category.
The multinational EAGLES (Evaluating Adverse Events in a
Global Smoking Cessation Study; Anthenelli et al., 2016), which
compared the non‐nicotine medications varenicline and bupropion
with an active comparator (transdermal nicotine patch, NRT) and
placebo in smokers with/without mental health conditions, provides
a unique opportunity to address these knowledge gaps. With
approximately 20% (n = 787) of the EAGLES psychiatric cohort
having a primary AD diagnosis, it is the largest sample of smokers
with AD ever enrolled in a placebo‐ and active‐controlled RCT for
smoking cessation treatments, and the first to compare all three
first‐line smoking cessation aids head‐to‐head in such smokers. In
this planned secondary analysis we compare the safety and efficacy
of varenicline, bupropion, NRT, and placebo across AD subcohorts
(PTSD, GAD, and PD), and compare clinical characteristics and rates
of clinically significant neuropsychiatric adverse events (NPSAEs)
and cessation in smokers with AD versus a cohort of smokers
without psychiatric disorders.
2 | MATERIALS AND METHODS
2.1 | Study design
EAGLES was a multinational RCT (ClinicalTrials.gov identifier
NCT01456936) conducted at the request of the FDA and European
Medicines Agency. It was an active treatment‐ (transdermal nicotine
patch, NRT) and placebo‐controlled trial of varenicline and bupropion
for 12 weeks, with a 12‐week nontreatment follow‐up assessment.
Institutional review boards or ethics committees at participating
institutions approved the study procedures. The study adhered to the
Declaration of Helsinki and the International Conference on
Harmonization Good Clinical Practice Guidelines. All patients signed
informed consent. The main outcome paper provides details of the
study design (Anthenelli et al., 2016). Here we present a post hoc
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subgroup analysis of the EAGLES safety and efficacy outcomes
identical to the parent trial.
2.2 | Participants
Eligible participants were adults aged 18–75 years who smoked an
average of ≥10 cigarettes/day with an exhaled carbon monoxide (CO)
>10 parts per million (ppm) at screening and wanted to stop smoking.
AD subcohort participants met diagnostic criteria based on the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision (DSM‐IV‐TR) for primary PD (with/without agorapho-
bia; n = 277), PTSD (n = 192), or GAD (n = 243), confirmed by the
Structured Clinical Interview for DSM‐IV‐TR Axis I Disorders (SCID‐I;
American Psychiatric Association, 2000; First, Gibbon, Spitzer,
Williams, & Benjamin, 1997). Smokers with a primary diagnosis of
obsessive‐compulsive disorder (n = 27) and social phobia disorder
(n = 48) were also enrolled in the parent trial but not included in the
present analysis because of the small sample size (Figure S1).
Participants could have a comorbid psychiatric diagnosis, provided it
did not prevent the participant from complying with study require-
ments. If the comorbid diagnosis was a substance‐use disorder, the
participant was required to be in sustained full remission to be
eligible. AD participants must have been considered psychiatrically
stable as evidenced by no exacerbations of their psychiatric condition
in the prior 6 months and if on pharmacotherapy, to have been on a
stable dose for ≥3 months. They could not be considered at high risk
of self‐injurious or suicidal behavior. Nonpsychiatric cohort (NPC)
participants were confirmed via SCID to have no major psychiatric
disorders (n = 4,028).
2.3 | Randomization and treatment
In EAGLES, participants were stratified into one of four psychiatric
subcohorts that included those individuals with AD, or the NPC,
while also stratifying into one of four geographic regions. Subse-
quently, participants were randomized to study treatment in a
1:1:1:1 ratio using a computer‐generated schedule. They were not
randomized based on their specific AD diagnosis but stratified by
whether they had any AD. Participants received either varenicline
1 mg twice daily, bupropion 150 mg twice daily, transdermal
nicotine patch (NRT) 21 mg/day with taper, or placebo for 12
weeks. Treatment was administered in a double‐blind, triple‐dummy
fashion (i.e., participants received one active and two placebo
medications, or three placebo medications), and all assessments
were blinded throughout the study. All participants received brief
weekly smoking cessation counseling (e.g., managing withdrawal
and cravings) that lasted <10 min and was based on US Agency for
Healthcare Research and Quality Guidelines (Fiore et al., 2008). No
routine mental health counseling was provided for mental health
issues, including ADs.
2.4 | Outcomes
2.4.1 | Safety
The primary safety outcome was the occurrence of any moderate to
severe NPSAEs, which were operationally defined with guidance
from the FDA (Anthenelli et al., 2016). Criteria for the primary
neuropsychiatric endpoint required the four categories of NPSAEs
(anxiety, depression, feeling abnormal, or hostility) most commonly
associated with nicotine withdrawal to be rated as severe
(i.e., significantly interfering with functioning). The other 12
categories (agitation, aggression, delusions, hallucinations, homicidal
ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal
behavior, or completed suicide) were included in the primary
composite safety endpoint if they were rated as either moderate
(i.e., some interference with functioning) or severe in intensity.
Secondary safety endpoints included the incidence of each of the
individual components and the subset of NPSAEs that were rated
severe. We also examined general AEs of any intensity (mild,
moderate, or severe) including those in the neuropsychiatric domain.
2.4.2 | Efficacy
The primary efficacy outcome measure was continuous abstinence
rates weeks 9–12 (CAR9–12) and secondary efficacy was CARs
weeks 9–24 (CAR9–24). Continuous abstinence was defined by self‐
report of no smoking (even a puff), with an expired CO concentration
of ≤10 ppm (Benowitz et al., 2002). Seven‐day point prevalence
abstinence (PPA) rates at week 12 (end of treatment) and week 24
(end of follow‐up) were also evaluated as prespecified secondary
endpoints.
2.5 | Assessments
Psychiatric diagnoses were evaluated using SCID‐I and ‐II (First et al.,
1997; First, Spitzer, Gibbon, & Williams, 2002). The severity of
cigarette dependence was assessed at baseline with the Fagerström
Test for Cigarette Dependence (FTCD; Fagerström, 2012). Anxiety
and depression symptoms were assessed at baseline and serially over
time using the Hospital Anxiety and Depression Scale (HADS;
Zigmond & Snaith, 1983). The Buss‐Perry Aggression Questionnaire
(Buss & Perry, 1992) was used to assess trait aggression at baseline.
NPSAEs were assessed with open‐ended questions, direct observa-
tion, and a 25‐item semi‐structured Neuropsychiatric Adverse Events
Interview (Anthenelli et al., 2016; Anthenelli et al., 2013) done at
each study visit which solicited psychiatric complaints across the 16
domains that comprised the primary safety outcome. Further,
NPSAEs were evaluated through reports from family members or
responses on the HADS and Columbia Suicide Severity Rating Scale
(Posner et al., 2011).
AYERS ET AL. | 249
2.6 | Statistical analysis
Stepwise logistic regression (using a 5% level for entry/stay) was
used to model the safety and efficacy endpoints of interest. Design
terms for treatment, diagnostic subcohort, their interaction, and
region (US or non‐US), had forced inclusion (efficacy included cohort
by region interaction as well). Several baseline characteristics, both
numerical and categorical, formed the set of candidate covariate
terms. Safety analyses included all participants who took ≥1 dose of
randomized treatment. Efficacy analyses of CARs included all
randomized participants. Consistent with the Russell standard (West,
Hajek, Stead, & Stapleton, 2005), participants with missing smoking
data were considered nonabstinent. The final model summaries for
NPSAEs, CA9–12, CA9–24, and PPA at weeks 12 and 24 are
provided in Table ST1.
3 | RESULTS
3.1 | Baseline characteristics
There were 712 participants in the AD subcohort and 4,028 in the
NPC. Baseline demographic, smoking, and psychiatric characteristics
are displayed in Table 1 and demonstrate both AD subcohort and AD
diagnostic subcohorts effects. For example, smokers with AD were
more likely to be female, from the USA and of white race than NPC
smokers. Smokers with PD had higher FTCD scores than NPC
smokers. Smokers with AD had more psychiatric and substance‐use
comorbidity and greater lifetime suicidal ideation and behavior. In
particular, at least descriptively, smokers with PTSD had higher rates
of comorbid alcohol‐use disorder history, other psychiatric disorders,
prior suicidal ideation and/or behavior, and were less likely to be on
psychotropic medication than smokers with GAD and PD. As
expected, the HADS anxiety score was significantly higher among
all AD diagnostic subcohorts versus NPC smokers, with smokers with
GAD reporting the highest levels of anxiety. The HADS depression
scores were higher in smokers with GAD and PTSD than in those
with PD and NPC.
3.2 | Neuropsychiatric AEs
Table 2 illustrates the incidence of moderate to severe treatment‐
emergent NPSAEs in each subcohort, the incidence of each individual
component comprising the composite endpoint, and other prespecified
NPSAE safety endpoints (e.g., serious NPSAEs). There was a significant
AD subcohort effect (p = .0012), with smokers in all three AD
subcohorts (PTSD, 6.9%; GAD, 5.4%; PD, 6.2%) having an increased
incidence of moderate‐to‐severe NPSAEs versus NPC smokers (2.1%).
Across the AD subcohorts, the rates of treatment discontinuation due
to NPSAEs were similar, ranging from 1.3% (GAD) to 2.1% (PTSD).
Figure 1a displays the observed incidence of the primary
composite safety endpoint for each subcohort as a function of
treatment. Figure 1b depicts risk differences (RDs) and associated
95% confidence intervals (95% CIs) for contrasts comparing: (a)
treatments overall; (b) subcohorts; and (c) treatments within each
subcohort and the NPC. There were no significant differences in the
incidence of moderate to severe NPSAEs by treatment group, nor
were there any significant treatment‐by‐cohort interactions. Smokers
with PD were significantly more prone to experience moderate to
severe NPSAEs versus NPC smokers (RD = 4.0; 95% CI = 0.34–7.65).
3.3 | General AEs
Table 3 depicts 16 categories of psychosomatic AEs of any intensity
occurring in ≥5% of participants in any subcohort. Sleep disorders
and disturbances occurred at the highest rate (GAD, 26.7%).
Gastrointestinal AEs were the second‐most commonly reported AE
category (PTSD, 22.8%). Infections were the third‐most commonly
reported AE category (NPC, 21.4%), followed by anxiety‐related AEs
(PD, 19.0%) and headaches (PTSD, 15.9%). Interestingly, smokers
with PTSD endorsed the highest rates of AEs among the subcohorts
for 11 of 16 categories.
3.4 | Efficacy
Figure 2a shows the primary efficacy endpoint (CAR9–12) across
subcohorts as a function of treatment, while Figure 2b provides
effect size estimates for (a) treatments overall; (b) subcohorts; and (c)
treatments within each subcohort and the NPC. Smokers with PD
were significantly less likely to quit than NPC smokers (odds ratio
[OR] = 0.53; 95% CI = 0.31–0.88). Among smokers with PTSD, there
were no significant differences in CAR9–12 for any active treatment
versus placebo; however, ORs for varenicline and NRT versus
placebo were notably >3. Among smokers with GAD and PD,
varenicline demonstrated superior efficacy to placebo (OR = 4.53;
95% CI = 1.20–17.10; and OR = 8.49; 95% CI = 1.57–45.78,
respectively). Additionally, among smokers with PD, NRT
significantly improved quit rates versus placebo (OR = 7.42; 95%
CI = 1.37–40.35). Thus, although we found no frank interaction
between primary AD diagnosis and treatment response, there
appears to be beneficial effects on initiating smoking abstinence for
varenicline and NRT in smokers with AD.
The secondary efficacy endpoint, weekly PPA at weeks 12 and
24, are presented in Figure 3. Consistent with some of the
CAR9–12 results, these suggest the possibility of differential
treatment responses to the first‐line smoking cessation medica-
tions by primary AD diagnosis. For example, varenicline showed
superior efficacy to placebo on 7‐day PPA at week 12 in smokers
with PTSD, GAD, and PD. This effect remained at week 24 among
smokers with GAD. In addition, varenicline was superior to
bupropion and NRT at week 12 among smokers with GAD. Among
smokers with PD, NRT was superior to placebo for 7‐day PPA at
both weeks 12 and 24.
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Observed CAR9–24 for varenicline, bupropion, NRT, and placebo
ranged from 7 to 13% (PTSD), 6–22% (GAD), 5–21% (PD), and 11–26%
(NPC), with placebo consistently the lowest (Figure S2). Within AD
subcohorts, estimated ORs versus placebo for CAR9–24 were >2 for all
active treatments, with the exception of bupropion and varenicline in
smokers with PTSD. However, the 95% CIs for all comparisons included
one, with the exception of NRT in smokers with PD, which continued to
demonstrate longer‐term efficacy in that subcohort.
TABLE 1 Baseline characteristics of all randomized participants by cohort
AD subcohortsa (N = 712)
NPC
(N = 4028)
p value for significant difference
(baseline variable by any cohort)b
PTSD
(n = 192)
GAD
(n = 243) PD (n = 277)
Demographic characteristics
Female, n (%) 107 (55.7) 149 (61.3) 183 (66.1) 2006 (49.8) <.0001
Age (year), mean (SD) 45.1 (12.0) 47.5 (11.6) 44.5 (11.7) 45.9 (12.9) .0465 (GAD > PD)
Race, n (%) .0003
White 156 (81.3) 203 (83.5) 258 (93.1) 3324 (82.5)
Black 23 (12.0) 33 (13.6) 14 (5.1) 514 (12.8)
Other 12 (6.3) 7 (2.9) 5 (1.8) 190 (4.7)
Region, n (%) .0024
US 115 (59.9) 150 (61.7) 98 (35.4) 1901 (47.2)
Non‐USc 77 (40.1) 93 (38.3) 179 (64.6) 2127 (52.8)
BMI (kg/m2), mean (SD) 28.1 (7.0) 28.1 (6.4) 27.1 (5.8) 27.6 (6.1) NS
Smoking characteristics
FTCD score, mean (SD) 5.8 (2.1) 5.9 (2.0) 6.1 (2.1) 5.5 (2.0) <.0001 (PD >NPC)
Duration of smoking (year), mean (SD) 26.8 (12.4) 28.5 (11.6) 26.9 (11.3) 28.1 (12.8) NS
Cigarettes smoked per day in past
month (n), mean (SD)
21.0 (8.9) 21.0 (7.9) 21.4 (7.7) 20.7 (8.0) NS
Previous quit attempts (n), mean (SD) 3.6 (6.2) 3.1 (5.3) 2.4 (3.7) 3.2 (9.7) NS
Prior use of study treatments
Varenicline, n (%) 26 (13.5) 40 (16.5) 48 (17.3) 578 (14.3) NS
Bupropiond, n (%) 21 (10.9) 27 (11.1) 26 (9.4) 373 (9.3) NS
NRT, n (%) 48 (25.0) 67 (27.6) 70 (25.3) 998 (24.8) NS
Psychiatric characteristics
Any comorbid Axis I diagnosis, n (%) 100 (52.1) 107 (44.0) 93 (33.6) 15 (0.4) <.0001
Substance‐use disorder history, n (%) 53 (27.6) 57 (23.5) 41 (14.8) 8 (0.2) <.0001
Alcohol‐use disorder history 39 (20.3) 43 (17.7) 30 (10.8) 6 (0.1)
Lifetime suicide‐related history from
C‐SSRS, n (%)
66 (34.9) 46 (19.2) 43 (15.7) 194 (4.9) <.0001
Suicidal ideation 66 (34.9) 46 (19.2) 42 (15.3) 190 (4.8)
Suicidal behavior 23 (12.2) 10 (4.2) 6 (2.2) 28 (0.7)
HADS score, mean (SD)
Anxiety subscale score 5.6 (3.8) 6.6 (4.0) 4.9 (3.8) 2.8 (2.7) <.0001 (GAD > PTSD > PD >NPC)
Depression subscale score 3.2 (3.4) 3.3 (3.1) 2.3 (2.9) 1.5 (2.1) <.0001 (GAD, PTSD > PD >NPC)
BPAQ score, mean (SD) 59.8 (18.0) 59.1 (18.2) 57.5 (17.4) 52.2 (15.4) <.0001 (PTSD, GAD, PD >NPC)
Receiving psychotropic medication at
enrolment, n (%)
53 (27.6) 122 (50.2) 146 (52.7) 329 (8.2) <.0001
Antidepressants 29 (15.1) 73 (30.0) 108 (39.0) 105 (2.6)
Anxiolytics, hypnotics, and other
sedatives
29 (15.1) 63 (25.9) 62 (22.4) 225 (5.6)
Antipsychotics 12 (6.3) 6 (2.5) 10 (3.6) 13 (0.3)
Mood stabilizers 0 (0.0) 4 (1.6) 2 (0.7) 20 (0.5)
Othere 0 (0.0) 2 (0.8) 0 (0.0) 6 (0.1)
Abbreviations: AD, anxiety disorder; BMI, body mass index; BPAQ, Buss–Perry Aggression Questionnaire; C‐SSRS, Columbia Suicide Severity Rating
Scale; FTCD, Fagerström Test for Cigarette Dependence; GAD, generalized anxiety disorder; HADS, Hospital Anxiety and Depression Scale; NPC,
nonpsychiatric cohort; NRT, nicotine‐replacement therapy (i.e., transdermal nicotine patch); NS, not significant; PD, panic disorder (with/without
agoraphobia); PTSD, posttraumatic stress disorder; SD, standard deviation.
a80 participants from the AD subcohort with social phobia disorders (n = 48), obsessive‐compulsive disorders (n = 27), and without psychiatric disorders
(n = 5) were excluded from the present analyses.
bp value for second‐level comparison of baseline variable by any cohort (i.e., PTSD, GAD, PD, or NPC).
cArgentina, Australia, Brazil, Bulgaria, Denmark, Canada, Chile, Finland, Germany, Mexico, New Zealand, Russia, Slovakia, South Africa, and Spain.
dBupropion prior use for smoking cessation or other indications.
ePsychostimulants, amino acids, and herbals or botanicals.
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4 | DISCUSSION
Our results from the largest, prospective, placebo‐controlled RCT of
smoking cessation medications in smokers with AD provide evidence
that varenicline, bupropion, and NRT are generally well tolerated in
smokers with PTSD, GAD, and PD, and that varenicline and NRT aid
quitting in these diagnostic subgroups, albeit at rates lower than in
smokers without mental health conditions.
Like smokers with other mental health conditions (Anthenelli
et al., 2016; Evins et al., 2019), smokers with primary diagnoses of
PTSD, GAD, and PD with/without agoraphobia were each more likely
to experience moderate to severe NPSAEs during a quit attempt than
smokers without mental health conditions, regardless of treatment.
This finding is not surprising given the overlap of ADs and heightened
anxiety sensitivity (Abrams et al., 2017) and distress intolerance
(Farris et al., 2016a). Although the psychiatric NPSAE events that
comprised the primary safety outcome had to be severe enough to
interfere significantly with functioning, it is possible that hyperar-
ousal to symptoms in smokers with AD contributed to a greater
occurrence of NPSAEs. We also found that compared with smokers
without mental health conditions, diagnostic subgroups of smokers
with AD had higher baseline levels of state anxiety, histories of
suicidal ideation/behavior, and were more likely to be white females
—variables we have previously reported were independently
associated with heightened NPSAE risk (Anthenelli et al., 2019).
However, our data on the incidence of these events in subtypes of
smokers with AD provides some reassurance that they occur
relatively infrequently and are not related to any specific pharma-
cotherapy. Of particular interest given the prior concerns about the
use of varenicline in smokers with PTSD (Campbell & Anderson,
2010; Cunningham et al., 2016) is that these events occurred most
commonly with placebo and were lowest with the two non‐nicotine
medications (Figure 1a).
Based on CAR9–12 outcomes and the 95% CIs overlapping one, it
would appear at first glance that smokers with PTSD might not
respond to any of the three first‐line medications. However, closer
inspection of the ORs (>3 for both varenicline and NRT vs. placebo)
for the CAR9–12 data and the significant effect (OR = 4.04; 95%
TABLE 2 Incidence of moderate and severe treatment‐emergenta neuropsychiatric adverse events (primary endpoint) among treated
participants collapsed across treatment arms
AD subcohorts (N = 703)
NPC
(N = 3,984)
Comparative
p valueb
PTSD
(n = 189)
GAD
(n = 240) PD (n = 274)
Observed incidence of the primary composite NPSAE
endpointc, n (%)
13 (6.9) 13 (5.4) 17 (6.2) 84 (2.1) <.0001
Estimated primary composite NPSAE endpoint, % (95% CI) 5.22 (1.58,
8.85)
4.74 (1.80,
7.68)
5.42 (2.63,
8.22)
1.43 (0.70,
2.16)
Observed components of primary composite NPSAE endpoint
≥1% in any cohort, n (%)
Anxiety 1 (0.5) 3 (1.3) 2 (0.7) 4 (0.1) .0003
Depression 3 (1.6) 0 (0.0) 1 (0.4) 1 (<0.1) <.0001
Agitation 7 (3.7) 6 (2.5) 3 (1.1) 51 (1.3) .0209
Aggression 1 (0.5) 4 (1.7) 5 (1.8) 11 (0.3) .0001
Panic 2 (1.1) 2 (0.8) 7 (2.6) 8 (0.2) <.0001
Observed events in the primary composite NPSAE endpoint
of severe intensity only, n (%)
3 (1.6) 6 (2.5) 3 (1.1) 13 (0.3) <.0001
Observed components of primary composite NPSAE endpoint
of severe intensity only and ≥1% in any cohort, n (%)
Anxiety 1 (0.5) 3 (1.3) 2 (0.7) 4 (0.1) .0003
Depression 3 (1.6) 0 (0.0) 1 (0.4) 1 (<0.1) <.0001
Events in the primary endpoint, n (%)
Serious adverse events 0 (0.0) 1 (0.4) 0 (0.0) 6 (0.2) .6056
Resulting in permanent treatment discontinuations 4 (2.1) 3 (1.3) 4 (1.5) 17 (0.4) .0024
Combined serious adverse events, severe adverse events,
and leading to treatment discontinuations or interventions
(at least one of)
5 (2.6) 6 (2.5) 5 (1.8) 27 (0.7) .0005
C‐SSRS‐ascertained suicidal ideation and/or behavior, n (%) 20 (10.6) 6 (2.6) 3 (1.1) 27 (0.7) <.0001
Ideation 20 (10.6) 6 (2.6) 3 (1.1) 26 (0.7) <.0001
Behavior 2 (1.1) 0 (0.0) 0 (0.0) 3 (0.1) .0007
Abbreviations: AD, anxiety disorder; CI, confidence interval; C‐SSRS, Columbia Suicide Severity Rating Scale; GAD, generalized anxiety disorder; NPC,
nonpsychiatric cohort; NPSAE, neuropsychiatric adverse event; PD, panic disorder (with/without agoraphobia); PTSD, posttraumatic stress disorder.
aOccurring any time during 12 weeks of treatment and ≤30 days after the last dose.
bComparative p values are via the χ2 test, not adjusted for multiplicity, and intended for descriptive purposes only.
cp = .0012 for AD subcohorts versus NPC.
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Varenicline vs. placebo 2.80 (−6.63, 12.23)
Bupropion vs. placebo 4.07 (−7.42, 15.54)
NRT vs. placebo −2.08 (−10.59, 6.43)
Varenicline vs. placebo −0.18 (−9.57, 9.21)
Bupropion vs. placebo 4.92 (−6.48, 16.32)
NRT vs. placebo −0.75 (−10.18, 8.68)
Varenicline vs. placebo −1.19 (−2.68, 0.30)
Bupropion vs. placebo <−0.01 (−1.68, 1.67)
NRT vs. placebo 0.04 (−1.87, 1.95)
Varenicline vs. placebo −7.73 (−21.95, 6.49)
Bupropion vs. placebo −10.19 (−23.04, 2.67)
NRT vs. placebo −3.03 (−18.41, 12.35)
NPC
PD
GAD
PTSD
Varenicline vs. placebo −1.58 (−6.46, 3.31)
Bupropion vs. placebo −0.30 (−5.51, 4.91)
NRT vs. placebo −1.45 (−6.44, 3.54)
GAD vs. PTSD −0.48 (−6.48, 5.52)
PD vs. PTSD 0.21 (−5.69, 6.11)
GAD vs. PD −0.69 (−5.90, 4.52)
PTSD vs. NPC 3.79 (−0.96, 8.54)
GAD vs. NPC 3.31 (−0.54, 7.16)
PD vs. NPC 4.00 (0.34, 7.65)
Cohort comparison
Treatment comparison
Treatments within cohort comparison 
RD (95% CI)(b)
F IGURE 1 Incidence of neuropsychiatric adverse events (a) and risk differences (b) in the anxiety disorder subcohorts versus nonpsychiatric
cohort. Period for the ascertainment of neuropsychiatric adverse events is during 12 weeks of treatment and ≤30 days after the last dose. The
following variables were included in the risk‐difference model: treatment group, anxiety disorder subcohort, treatment‐by‐subcohort
interaction, and region (US or non‐US). AD, anxiety disorder; CI, confidence interval; GAD, generalized anxiety disorder; NPC, nonpsychiatric
cohort; NPSAE, neuropsychiatric adverse event; NRT, nicotine replacement therapy (i.e., transdermal nicotine patch); PD, panic disorder (with/
without agoraphobia); PTSD, posttraumatic stress disorder; RD, risk difference
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CI = 1.39–11.74) for varenicline versus placebo for 7‐day PPA at
week 12 (Figure 3) might make such an interpretation premature.
Thus, we conclude that while overall smokers with PTSD had 42%
lower odds of quitting versus smokers without mental health
conditions, varenicline and NRT hold promise in these difficult‐to‐
treat smokers, while there is less of a signal for bupropion. However,
larger head‐to‐head studies are needed to test those hypotheses
because some studies have found beneficial effects for bupropion in
smokers with PTSD (Hertzberg, Moore, Feldman, & Beckham, 2001;
McFall et al., 2010). Our finding is consistent with a retrospective,
open‐label trial of varenicline (Okoli, Wiggins, Fallin‐Bennett, &
Rayens, 2017), and a concurrent varenicline and prolonged‐exposure
therapy trial in smokers with PTSD (Foa et al., 2017), both of which
showed beneficial effects of varenicline in smokers with PTSD. They
are also consistent with nonplacebo‐controlled trials of NRT
(Hertzberg et al., 2013; Kelly et al., 2015a; Kelly et al., 2015b;
McFall et al., 2010) showing beneficial effects in smokers with PTSD.
Among smokers with GAD, we observed a pattern of results
similar to that found in smokers with heterogeneous mental health
conditions that we described in our initial report (Anthenelli et al.,
2016): odds of quitting were highest for varenicline versus other
active treatments. However, in contrast to those results, and likely
due to the limited power in the GAD subcohort, the effects for
bupropion (OR = 2.43; 95% CI = 0.57–10.31) and for NRT (OR= 2.44;
95% CI = 0.58–10.34) versus placebo did not reach statistical
significance in these smaller samples. Nonetheless, we conclude that
all three medications might show efficacy in smokers with GAD,
albeit with varenicline having a larger effect based on the significant
7‐day PPA at week 12 comparisons.
Smokers with PD with/without agoraphobia appeared to respond
similarly to NRT and varenicline. In fact, for CAR9–12 as well as 7‐
day PPA at week 12, both medications were superior to placebo. This
equivalent pattern of response, while similar to that for CAR9–12 in
smokers with PTSD, is the first we have observed among any
psychiatric subcohort of smokers we have studied to date in EAGLES,
who typically show the pattern we described previously, wherein
varenicline is better than bupropion and NRT, and all are better than
placebo (Anthenelli et al., 2016). This novel finding warrants
replication, but it is interesting to note that varenicline and NRT
partially or fully agonize nicotinic acetylcholine receptors and
ameliorate nicotine withdrawal, which has been found to be more
severe in certain smokers with AD prone to negative reinforcement‐
based smoking (Farris et al., 2016b; Leventhal & Zvolensky, 2015).
To our knowledge, there has been only one other placebo‐
controlled trial of bupropion, NRT, and combinations thereof in
smokers with AD to date. Piper and colleagues (Piper et al., 2011)
retrospectively examined the relationship between ADs (including
panic attack, social anxiety disorder, and GAD) and reported that
neither bupropion, NRT, nor their combination was more effective
than placebo and counseling. Our group found some differences
among smokers with AD in that varenicline provided significant
benefit for cessation in those with GAD and PD, while NRT provided
TABLE 3 Mild, moderate, or severe treatment‐emergent adverse eventsa reported by ≥5% of participants in any subcohort
Adverse event, n (%)
AD subcohorts (N = 703)
NPC (n = 3,984) Comparative p valuebPTSD (n = 189) GAD (n = 240) PD (n = 274)
Gastrointestinal motility and defecation conditions 15 (7.9) 9 (3.8) 22 (8.0) 252 (6.3) .1850
Gastrointestinal signs and symptoms 43 (22.8) 40 (16.7) 60 (21.9) 697 (17.5) .0824
Administration‐site reactions 11 (5.8) 8 (3.3) 10 (3.6) 180 (4.5) .5746
General system disorders NEC 21 (11.1) 16 (6.7) 28 (10.2) 333 (8.4) .2792
Infections—pathogen unspecified 35 (18.5) 41 (17.1) 56 (20.4) 852 (21.4) .3434
Viral infectious disorders 11 (5.8) 8 (3.3) 13 (4.7) 152 (3.8) .4509
Injuries NEC 15 (7.9) 8 (3.3) 18 (6.6) 0 (0.0) <.0001
Joint disorders 10 (5.3) 5 (2.1) 6 (2.2) 75 (1.9) .0149
Headaches 30 (15.9) 22 (9.2) 30 (10.9) 447 (11.2) .1648
Neurological disorders NEC 21 (11.1) 31 (12.9) 39 (14.2) 317 (8.0) .0002
Anxiety disorders and symptoms 32 (16.9) 40 (16.7) 52 (19.0) 369 (9.3) <.0001
Depressed‐mood disorders and disturbances 21 (11.1) 15 (6.3) 22 (8.0) 177 (4.4) <.0001
Mood disorders and disturbances NEC 20 (10.6) 21 (8.8) 19 (6.9) 201 (5.0) .0008
Sleep disorders and disturbances 42 (22.2) 64 (26.7) 64 (23.4) 787 (19.8) .0338
Respiratory disorders NEC 15 (7.9) 7 (2.9) 10 (3.6) 219 (5.5) .0709
Epidermal and dermal conditions 17 (9.0) 13 (5.4) 12 (4.4) 186 (4.7) .0552
Abbreviations: AD, anxiety disorder; GAD, generalized anxiety disorder; NEC, not elsewhere classified; NPC, nonpsychiatric cohort; PD, panic disorder
(with/without agoraphobia); PTSD, posttraumatic stress disorder.
aAs classified by the Medical Dictionary for Regulatory Activities (MedDRA, v18.0) high‐level group terms, and occurring any time during 12 weeks of
treatment and ≤30 days after the last dose.
bComparative p values are via the χ2 test, not adjusted for multiplicity, and intended for descriptive purposes only.
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Treatments within cohort comparison
Varenicline vs. placebo 4.77 (2.44, 9.34)
Bupropion vs. placebo 2.18 (1.06, 4.48)
NRT vs. placebo 3.38 (1.71, 6.70)
GAD vs. PTSD 1.25 (0.61, 2.58)
PTSD vs. NPC 0.58 (0.33, 1.01)
GAD vs. NPC 0.72 (0.45, 1.16)
PD vs. NPC 0.53 (0.31, 0.88)
Varenicline vs. bupropion 2.19 (1.25, 3.86)
Varenicline vs. NRT 1.41 (0.84, 2.37)
Bupropion vs. NRT 0.65 (0.36, 1.15)
PD vs. PTSD 0.92 (0.43, 1.94)
GAD vs. PD 1.37 (0.69, 2.72)
Varenicline vs. placebo 4.53 (1.20, 17.10)
Bupropion vs. placebo 2.43 (0.57, 10.31)
NRT vs. placebo 2.44 (0.58, 10.34)
Varenicline vs. placebo 8.49 (1.57, 45.78)
Bupropion vs. placebo 3.33 (0.58, 19.26)
NRT vs. placebo 7.42 (1.37, 40.35)
Varenicline vs. placebo 4.18 (3.10, 5.64)
Bupropion vs. placebo 2.33 (1.71, 3.17)
NRT vs. placebo 2.37 (1.74, 3.22)
Varenicline vs. placebo 3.23 (0.67, 15.67)
Bupropion vs. placebo 1.20 (0.21, 6.84)
NRT vs. placebo 3.05 (0.64, 14.47)
OR (95% CI)
(b)
F IGURE 2 Observed continuous abstinence rates (a) and odds ratios (b) for weeks 9–12. The following variables were included in the odds‐
ratio model: treatment group, anxiety disorder subcohort, treatment‐by‐subcohort interaction, region (US or non‐US), race, age, Fagerström
Test for Cigarette Dependence, and cigarettes smoked/day in the past month. AD, anxiety disorder; CAR, continuous abstinence rate; CI,
confidence interval; GAD, generalized anxiety disorder; NPC, nonpsychiatric cohort; NRT, nicotine replacement therapy (i.e., transdermal
nicotine patch); OR, odds ratio; PD, panic disorder (with/without agoraphobia); PTSD, posttraumatic stress disorder
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(a)
(b)
F IGURE 3 Observed 7‐day point prevalence of abstinence during treatment and follow‐up and odds ratios at week 12 and week 24
by cohort. The following variables were included in the odds‐ratio model: treatment group, anxiety disorder subcohort, treatment‐by‐
subcohort interaction, and region (US or non‐US) and region‐by‐cohort interaction. CI, confidence interval; GAD, generalized anxiety
disorder; NPC, nonpsychiatric cohort; NRT, nicotine replacement therapy (i.e., transdermal nicotine patch); OR, odds ratio; PD, panic
disorder (with/without agoraphobia); PPA, point prevalence of abstinence; PTSD, posttraumatic stress disorder
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(d)
F IGURE 3 Continued
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significant benefit for those with PD. The discrepancy with our
results and Piper’s investigation may have had to do with that group’s
smaller sample size, use of a structured interview that included
lifetime diagnoses, and diagnostic differences (e.g., history of panic
attacks vs. PD). Additional investigations (Gaspersz et al., 2017)
examined anxiety in depressed patients and suggested that smokers
with comorbid AD may be less able to deal with the stress and
challenges of smoking cessation. While our results supported the
idea that smokers with AD have lower rates of abstinence and higher
rates of AEs during a cessation attempt than smokers with no
psychiatric disorder, we also present evidence that first‐line
smoking cessation treatments do indeed work in those with ADs.
ORs for CAR9–12 for active treatments versus placebo ranged from
1.20 to 3.23 (PTSD), 2.43–4.53 (GAD), and 3.33–8.49 (PD). Thus,
clinicians should utilize these treatments, as they produce clinical
gains and do not increase the risk of moderate to severe NPSAEs,
which occurred at low frequency overall and with no differences
between treatment groups. Of note, there was lower efficacy of
smoking cessation treatment on longer‐term (CAR9–24) outcomes
indicating smokers with ADs may require prolonged pharmacother-
apy use or continued smoking cessation counseling.
The primary limitations of this study are related to general-
izability. This study did not include individuals who were psychia-
trically unstable or those with current substance‐use disorders. The
most recent DSM‐5 no longer categorizes PTSD as an AD, but rather,
a trauma‐related disorder; nonetheless, there is substantial overlap
in the symptoms of PTSD and ADs. Small samples of those with social
phobia disorder and obsessive‐compulsive disorder limited our ability
to evaluate these diagnostic groups. Given the post hoc nature of this
study, we did not adjust for multiple comparisons, which increases
the probability of a Type I error. Finally, this study was not powered
or stratified a priori for this subcohort analysis.
In conclusion, individuals with primary PTSD, GAD, and PD were
approximately three times more likely to experience clinically
significant NPSAEs during medication‐assisted cessation attempts
and were 28% (GAD) to 47% (PD) less likely to quit than smokers
without mental health conditions. The incidence of moderate to severe
NPSAEs was similar across the three AD subcohorts and not related to
any specific smoking cessation treatment. Despite limited power in
some diagnostic subcohorts, compared with placebo and counselling,
varenicline boosted odds of quitting threefold in smokers with PTSD
(95% CI = 0.67–15.67), 4.5‐fold in smokers with GAD (95%
CI = 1.20–17.10), and 8.5‐fold in PD smokers (95% CI = 1.57–45.78).
Additionally, among PD smokers, NRT improved quit rates approxi-
mately 7.5‐fold versus placebo (95% CI = 1.37–40.35) while also
tripling the quit rate in smokers with PTSD (95% CI = 0.64–14.47). Our
results demonstrate that the first‐line (varenicline, bupropion, NRT)
smoking cessation treatments are effective at least in the short‐term
for smokers with PTSD, GAD, and PD. Smokers with AD, particularly
those with PTSD, are not all alike with respect to their baseline
smoking and psychiatric characteristics, AE patterns, and treatment
response. Differences between distinct anxiety and trauma‐related
disorders should be further explored. Regardless of whether there are
larger clinical trials in the future, smoking cessation efforts utilizing
these first‐line treatments should be considered for smokers with ADs.
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